Biomarker Window of Opportunity Study to Evaluate the Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Trial Profile

Biomarker Window of Opportunity Study to Evaluate the Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 25 May 2018

At a glance

  • Drugs Ribociclib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 14 May 2018 Status changed from not yet recruiting to recruiting.
    • 06 Feb 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
    • 06 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top